泛RAF与SRC家族激酶抑制剂CCT3833在突变KRAS驱动癌症中有效
本研究报道新药CCT3833同时抑制RAF和SRC激酶,在KRAS突变肿瘤的体外和体内实验中抑制肿瘤生长且耐受良好。CCT3833在I期临床试验中显著延长一例G12V KRAS梭形细胞肉瘤患者的无进展生存期,该患者对多激酶抑制剂无应答。基于临床前数据和该I期临床未确认应答,CCT3833需在其它KRAS突变癌症患者中进一步评估。
要点
- CCT3833同时抑制RAF和SRC,在KRAS突变结直肠、肺和胰腺肿瘤异种移植中显示疗效。
- I期试验中CCT3833显著延长一例G12V KRAS梭形细胞肉瘤患者的无进展生存期。
- CCT3833需在其它KRAS突变癌症患者中进一步评估。
核心结论
- CCT3833在KRAS突变结直肠、肺和胰腺肿瘤异种移植中显示显著临床前疗效,提示对多个未满足临床需求领域有治疗选择。
研究设计与样本
- 研究描述了新药CCT3833同时抑制RAF和SRC,并在KRAS突变肿瘤中进行体外和体内实验及I期临床试验(NCT02437227)。
主要发现
- CCT3833在体外和体内抑制KRAS突变肿瘤中的RAF和SRC,在小鼠中以良好耐受剂量抑制肿瘤生长。
- I期试验中CCT3833显著延长一例对多激酶抑制剂无应答的G12V KRAS梭形细胞肉瘤患者的无进展生存期。
临床怎么用
- 基于临床前数据和I期临床未确认应答,CCT3833需在其它KRAS突变癌症患者中进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mutant forms of KRAS are limited, largely because the complexity of downstream signaling and feedback mechanisms mean that targeting individual pathway components is ineffective. DESIGN: The protein kinases RAF and SRC are validated therapeutic targets in KRAS-mutant pancreatic ductal adenocarcinomas, colorectal cancers and non-small-cell lung cancers and we show that both must be inhibited to block growth of these cancers. We describe CCT3833, a new drug that inhibits both RAF and SRC, which may be effective in KRAS-mutant cancers. RESULTS: We show that CCT3833 inhibits RAF and SRC in KRAS-mutant tumors in vitro and in vivo, and that it inhibits tumor growth at well-tolerated doses in mice. CCT3833 has been evaluated in a phase I clinical trial (NCT02437227) and we report here that it significantly prolongs progression-free survival of a patient with a G12VKRAS spindle cell sarcoma who did not respond to a multikinase inhibitor and therefore had limited treatment options. CONCLUSIONS: New drug CCT3833 elicits significant preclinical therapeutic efficacy in KRAS-mutant colorectal, lung and pancreatic tumor xenografts, demonstrating a treatment option for several areas of unmet clinical need. Based on these preclinical data and the phase I clinical unconfirmed response in a patient with KRAS-mutant spindle cell sarcoma, CCT3833 requires further evaluation in patients with other KRAS-mutant cancers.
引用
- Saturno G, Lopes F, Niculescu-Duvaz I, et al. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann Oncol. 2020. PMID: 33130216. doi:10.1016/j.annonc.2020.10.483
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。